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Abstract
The primary analysis in many randomized controlled trials focuses on the average
treatment e↵ect and does not address whether treatment benefits are widespread or
limited to a select few. This problem a↵ects many disease areas, since it stems from
how randomized trials, often the gold standard for evaluating treatments, are designed
and analyzed. Our goal is to learn about the fraction who benefit from a treatment,
based on randomized trial data. We consider the case where the outcome is ordi-
nal, with binary outcomes as a special case. In general, the fraction who benefit is
a non-identifiable parameter, and the best that can be obtained are sharp lower and
upper bounds on it. Our main contributions include (i) showing that the naive (plug-
in) estimator of the bounds can be inconsistent, in the case that support restrictions
are made on the joint distribution of the potential outcomes (such as the no harm
assumption); (ii) developing the first consistent estimator for this case; (iii) apply-
ing this estimator to a randomized trial dataset of a medical treatment to determine
whether the estimates can be informative. Our estimator is computed using linear
programming, allowing fast implementation. R and MATLAB software are provided
(https://github.com/emhuang1/fraction-who-benefit).
Keywords. Non-identifiable parameter; Randomized trial; Treatment e↵ect hetero-
geneity.
⇤ehuang19@jhu.edu
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1 Introduction
We aim to make inferences about the fraction of the population who benefit from a treatment.
This fraction is defined in the potential outcomes framework. Each participant has two
potential outcomes, one representing the participant’s outcome if assigned to treatment and
the other if assigned to control. The fraction who benefit is defined as the fraction of the
population whose potential outcome under treatment is better than that under control. In
other words, it is the fraction who would be better o↵ under treatment than under control.
The fraction who benefit is generally a non-identifiable parameter. This is due to the
fundamental problem of causal inference, which is that we can observe only one of the poten-
tial outcomes for any individual (Holland, 1986). However, sharp bounds on the fraction are
identifiable (Williamson and Downs, 1990; Manski, 1997; Fan and Park, 2009, 2010; Kim,
2014). We develop a new method to estimate bounds using randomized trial data, when
the outcome is ordinal. The bounds are based on the marginal distributions of the potential
outcomes and can also incorporate a prognostic baseline variable, support restrictions on the
joint distribution of the potential outcomes, or both.
Our main contributions include (i) showing that the naive (plug-in) estimator of the
bounds can be inconsistent in the case where support restrictions are made (such as the no
harm assumption); (ii) developing the first consistent estimator for this case; (iii) applying
this estimator to a randomized trial dataset of a medical treatment to determine whether
the estimates can be informative. An advantage of the proposed estimator is that it can
be computed using linear programming, i.e., the optimization of a linear objective function
subject to linear equality and inequality constraints (Vanderbei, 2013). Linear programming
has readily available software that is computationally e cient. The lower and upper bound
estimates are typically computed in under a second.
We apply our method to the MISTIE II (Minimally Invasive Surgery for Intracerebral
Hemorrhage Evacuation Phase II) randomized trial (Morgan et al., 2008), which compared a
new surgical intervention for stroke to standard medical management. As an example of our
results in one case, the lower and upper bound estimates on the fraction who benefit are 0.10
and 0.73 when the outcome is a rating of functional disability 180 days post-stroke, and 0.82
and 0.99 when the outcome is reduction in clot volume. Also, we conduct simulation studies
to evaluate the bias and standard error of the bound estimators, as well as the performance
of standard n-bootstrap and m-out-of-n bootstrap in constructing confidence intervals for
the bounds.
Related work includes Manski (1997); Gadbury et al. (2004); Fan and Park (2009, 2010);
Zhang et al. (2013); Kim (2014); Borusyak (2015). Manski (1997) derives sharp bounds on the
fraction who benefit, assuming no harm (i.e., for each individual, the potential outcome under
treatment is not worse than under control) and without using the marginal distributions
of the potential outcomes. Manski (1997) does not assume that treatment assignment is
independent of the potential outcomes, unlike our context of a randomized clinical trial
where this holds by design. Gadbury et al. (2004) derive bounds on the fraction harmed,
given the marginal distributions of the potential outcomes, for a binary outcome. They use
matched-pairs and extended matched-pairs designs to improve the bounds, while we use a
simple randomized trial design and consider a prognostic baseline variable and/or support
restrictions.
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Using copula theory, Fan and Park (2009, 2010) derive sharp bounds on the fraction
who benefit, given the marginal distributions of the potential outcomes. Kim (2014) derives
another set of bounds through optimal transportation theory, which can incorporate support
restrictions on the joint distribution of the potential outcomes. These bounds apply to
continuous outcomes, while our bounds apply to ordinal outcomes. Both Fan and Park (2009,
2010) and Kim (2014) provide estimators for their bounds. Kim’s method generally requires
solving a non-convex optimization problem when a support restriction is made. Non-convex
problems are much more computationally di cult to solve than linear programs, which are
used by our method.
Zhang et al. (2013) propose a method to directly estimate the fraction who benefit,
assuming that the potential outcomes are conditionally independent of each other given a
set of measured baseline covariates. Sensitivity analyses are used to address assumption
violations. Our method allows support restrictions, a di↵erent type of assumption than
conditional independence. Borusyak (2015) shows that, for a discrete outcome, one can
use linear programming to compute bounds on the fraction who are strong responders (i.e.,
the fraction whose magnitude of individual treatment e↵ect exceeds a threshold), given the
marginal distributions of the potential outcomes and assuming no harm. Borusyak does not
address estimation of these bounds; in contrast, our main focus is estimation.
The organization of our paper is as follows. We provide background on the MISTIE II
trial in Section 2. In Section 3, we define the bound parameters. In Section 4, we show
that the plug-in estimator can be inconsistent and propose an alternative estimator which
is consistent. We apply our estimator to the MISTIE II trial in Section 5, and present
simulation results in Section 6. We discuss future research directions in Section 7.
2 MISTIE II Trial
The data to be analyzed is from MISTIE II, a recently completed Phase II randomized trial
for intracerebral hemorrhage, a type of stroke that can impair cognitive/motor functions and
cause death (Morgan et al., 2008). The MISTIE II trial was designed to assess the e↵ec-
tiveness of image-guided minimally invasive surgery (i.e., treatment), relative to standard
medical care (i.e., control). There were 96 participants, with 54 assigned to treatment and
42 to control. The randomization ratio between study arms gave a higher likelihood of being
assigned to treatment, yielding the higher proportion of treatment participants.
In MISTIE II, the primary outcome was a rating of functional disability at 180 days after
stroke, measured by the modified Rankin Scale (mRS) (Quinn et al., 2009). The mRS score is
ordinal, defined as an integer between 0 and 6, with lower values corresponding to improved
functioning (Cheng et al., 2014). For example, 0 corresponds to no symptoms and 6 to death.
The original analysis categorized a patient’s outcome as successful if 180-day mRS  3.
For the primary analysis comparing treatment versus control, the average treatment e↵ect
(ATE) was used, i.e., the di↵erence in population proportions with a successful outcome.
The estimate of ATE was 0.11 (95% CI: [-0.09, 0.29]), using the 52 treatment and 38 control
participants with recorded 180-day mRS scores.
For a patient or clinician, it could also be useful to know the fraction who benefit from
treatment, with respect to functional disability at 180 days as measured by mRS. This is
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the fraction of patients who would have a better 180-day mRS score under treatment than
under control. Since this ATE only considers mRS in two categories ( 3 or > 3), it ignores
any benefit within a category, which in the MISTIE trial context is clinically meaningful. It
also does not provide an upper bound on the fraction who benefit.
In general, the population ATE is not designed to give information about the fraction
who benefit. For example, if the outcome is ordinal, the population ATE can be large while
the fraction who benefit is small; this would occur if the majority get zero benefit while a
minority have a large benefit.
3 Bound Parameters
3.1 Identifiable Components of Potential Outcome Distribution
Based on Randomized Trial
Denote YC and YT as the potential outcomes under control and treatment, respectively.
Suppose the outcome of interest is ordinal with L levels (i.e., 1, 2, .., L), ordered from least
to most favorable. For MISTIE, the outcome is mRS score recoded in this order, such that
L = 7, with 1 corresponding to death, and 7 to no symptoms.
Let X be a prognostic baseline variable measured in the randomized trial. For each
participant, define the vector including the baseline variable and both potential outcomes
as V = (X, YC , YT ). We let P denote a generic, joint distribution on (X, YC , YT ) and let P0
denote the true (unknown) distribution on these variables. We assume each participant’s
vector V is an independent, identically distributed draw from P0. Both values YC and YT
are never simultaneously observed on the same patient (Holland, 1986). Rather, we observe
(X,A, Y ), where A is the randomized treatment assignment (1 if treatment, 0 if control)
which is independent of V , and Y is the observed outcome corresponding to the treatment
assigned, i.e., Y = AYT + (1  A)YC .
Our goal is to learn about the fraction who benefit, i.e., the parameter  = P (YT > YC),
despite never observing the full pair of potential outcomes for any participant. Although
the fraction who benefit is non-identifiable, we can rule out certain possibilities based on
the marginal distributions of YC and YT , which are identifiable. Denote FC and FT as the
marginal distribution functions of YC and YT , respectively. The distribution FC is identifiable
because FC(y) = P (YC  y) = P (YC  y|A = 0) = P (Y  y|A = 0) for any y, and FT is
identifiable by the same principle. Section 3.2 presents bounds on  , as a function of FC and
FT . These bounds can be sharpened by incorporating a baseline variable X or by making
assumptions about the joint distribution of (YC , YT ), discussed in Section 3.3.
3.2 Sharp Bounds on the Fraction who Benefit, with Neither
Baseline Variable nor User-defined Assumptions
We present sharp bounds on the fraction who benefit, given only FC and FT . Define ⇡i,j as
the fraction of the population with (YC , YT ) = (i, j), i.e., ⇡i,j = P (YC = i, YT = j). Let L be
the set of integers from 1 to L. The ⇡i,j’s (i, j 2 L) form an L x L matrix representing the
joint distribution of the potential outcomes (JDPO), shown in Figure 1a for MISTIE. There,
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the row and column sums correspond to pC and pT , respectively, where pC(y) = P (YC = y)
and pT (y) = P (YT = y) for any y.
We partition the population into three categories based on potential outcomes (YC , YT ):
those for whom assignment to treatment (compared to control) would have no e↵ect, harm,
or benefit. These categories correspond to the colored regions in Figure 1a, where the
diagonal region (yellow) represents no e↵ect (YT = YC), the lower region (red) represents
harm (YT < YC), and the upper region (green) represents benefit (YT > YC). The parameter
 is the fraction of the population in the green region, i.e., the sum of ⇡i,j over indices
(i, j) with j > i. The value of  , in general, is non-identifiable since for each individual
we only observe one component of (YC , YT ), and therefore do not know which of the three
aforementioned regions this individual belongs to.
Let  l(FC , FT ) and  u(FC , FT ) denote the sharp lower and upper bounds on  , given only
FC and FT , i.e., the best possible bounds for  that could be obtained if FC , FT were known.
We say a joint distribution P 0 on (YC , YT ) is consistent with a pair of marginal distribution
functions FC , FT if the marginal distribution of YC under P 0 equals FC and the marginal
distribution of YT under P 0 equals FT . The bound parameter  l(FC , FT ) is formally defined
as the infimum of the fraction who benefit, among all joint distributions P 0 on (YC , YT )
consistent with FC and FT , i.e.,
 l(FC , FT ) = inf {P 0(YT > YC) : P 0 on (YC , YT ) consistent with FC and FT} (1)
= min
8>>><>>>:
X
j>i
i,j2L
⇡i,j :
⇡i,j   0 for all i, j 2 LPi
i0=1
PL
j=1 ⇡i0,j = FC(i) for all i = 1, .., L  1Pj
j0=1
PL
i=1 ⇡i,j0 = FT (j) for all j = 1, .., L  1PL
i=1
PL
j=1 ⇡i,j = 1
9>>>=>>>; . (2)
The bound  u, which can be derived analogously, equals (1) with sup in place of inf, and (2)
with max in place of min. It follows from the form of (2) that  l(FC , FT ) and  u(FC , FT ) can
be represented as linear programs. We sometimes drop their dependence on FC , FT when it
is clear from context.
Referring to Figure 1a, if one were to calculate
P
j>i ⇡i,j for every possible matrix of ⇡i,j’s
with row and column sums consistent with pC and pT , the bounds  l and  u would be the
minimum and maximum among them. Borusyak (2015) uses this concept to derive bounds
on the fraction who are strong responders. In the binary case (L = 2),  l and  u simplify
to max
 
0, pT (2)  pC(2)
 
and min
 
pC(1), pT (2)
 
, respectively (Gadbury et al., 2004).
3.3 General Formulation of Sharp Bounds on the Fraction who
Benefit
We generalize the bound formulation to incorporate a baseline variable, user-defined assump-
tions, or both. These can narrow the bounds because they o↵er new information.
We consider a baseline, i.e., pre-randomization, variable that is categorical and conjec-
tured to be prognostic for (i.e., correlated with) the outcome. For instance, a prognostic
baseline variable in MISTIE II is stroke severity, measured by the NIH Stroke Scale (NIHSS)
(Kreutzer et al., 2011). Define X as a baseline variable with K possible values (i.e., x1, .., xK ;
5
Hosted by The Berkeley Electronic Press
K <1). Let pX be the probability mass function of X, i.e.,
pX(xk) = P (X = xk) > 0 for any k = 1, .., K. (3)
Based on X, one can stratify the total population into K subpopulations, with weights
given by pX . For each k, let F kC and F
k
T be the marginal distribution functions of YC and
YT , respectively, for subpopulation k. That is, for any y,
F kC(y) = P (YC  y|X = xk), F kT (y) = P (YT  y|X = xk). (4)
Another way to potentially improve bounds on the fraction who benefit is to incorporate
user-defined assumptions about P based on subject matter knowledge. We focus throughout
on assumptions of the form P (YC = i, YT = j) = 0 for pairs (i, j) specified by the user.
These support restrictions on the joint distribution of (YC , YT ) are encoded by the indicator
function g : L⇥ L! {0, 1} that maps each potential outcome pair (yC , yT ) to 0 if the pair
is assumed not possible, and 1 otherwise. Equivalently, g(i, j) = 0 encodes the assumption
that ⇡i,j = 0. The support restrictions we consider in our application (Section 5) include:
• Restriction on harm: The harm of treatment is at most d (i.e., ⇡i,j = 0 if i   j > d).
No harm (i.e., ⇡i,j = 0 if i > j) is a special case.
• Restriction on benefit: The benefit of treatment is at most d (i.e. ⇡i,j = 0 if j  i > d).
Figure 1b illustrates the restriction on benefit with d = 3 for the MISTIE case. For con-
ciseness, we sometimes refer to user-defined assumptions as restrictions. We assume the
restrictions, i.e., the function g, is prespecified and known.
Let R be the subclass of joint distributions P 0 on (YC , YT ) that satisfy P 0(YC = i, YT =
j) = 0 whenever g(i, j) = 0. In other words, R is the subclass of joint distributions on
(YC , YT ) that satisfy the user-defined assumptions. If there are no user-defined assumptions,
then g maps to 1 for any (yC , yT ), and R includes all joint distributions on (YC , YT ). We
make the following assumption:
Assumption 1. The true joint distribution P0(X, YC , YT ) is consistent with R, i.e., the
distribution P0(YC , YT ), which is formed by marginalizing P0(X, YC , YT ) over X, is in R.
Let  R,Xl and  
R,X
u denote the sharp lower and upper bounds on  , respectively, incorpo-
rating the baseline variable X and user-defined assumptions R. These bounds are functions
of R and the identifiable components of P (X, YC , YT ) in a randomized trial where study arm
is assigned independent of X, i.e., the components {F kC , F kT }Kk=1 and pX . Formally, we have
 R,Xl =  
R,X
l ({F kC , F kT }Kk=1, pX) (5)
= inf
 
P 0(YT > YC) : P 0 on (X, YC , YT ) consistent with R, {F kC , F kT }Kk=1, pX
 
. (6)
The upper bound  R,Xu is (6), with sup in place of inf.
Let  Rl denote the lower bound with restrictions R but ignoring the baseline variable
X, i.e., (5)-(6) with {F kC , F kT }Kk=1, pX replaced by FC , FT . Similarly, let  Xl denote the lower
bound with the baseline variable but no restrictions R, i.e., (5)-(6) with R omitted. Anal-
ogous definitions apply for the upper bounds. The bounds  l, u from Section 3.2 are
equivalent to (5)-(6) with R omitted and {F kC , F kT }Kk=1, pX replaced by FC , FT .
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Each of the bound parameters  R,Xl , 
R
l , 
X
l , l is a function of the joint distribution P =
P (X, YC , YT ) through the corresponding identifiable components. E.g.,  
R,X
l =  
R,X
l (P )
depends on P through the components {F kC , F kT }Kk=1, pX of P ; the bound  l is a function of
P through the (less informative) components FC , FT . We suppress the dependence of these
parameters on P for conciseness.
Incorporating a baseline variable or restriction leads to a larger or equal lower bound,
and smaller or equal upper bound, as expressed in Theorem 1, proved in Appendix A:
Theorem 1. Consider any user-defined assumptions R, baseline variable X, and joint dis-
tribution P on (X, YC , YT ) that is consistent with R. Then we have  R,Xl   max{ Xl , Rl }
and min{ Xl , Rl }    l, where each bound parameter is evaluated at P .
An analogous claim holds for the upper bound parameters. Appendix A and all following
appendices can be found in the Supplementary Materials at the end of this document.
Restrictions R may be inconsistent with a set of marginal distributions {F kC , F kT }Kk=1, pX ,
i.e., there may not exist a joint distribution P 0 on (X, YC , YT ) that is consistent with both
R and {F kC , F kT }Kk=1, pX . In this case, the bound parameter (6) is undefined, since the set of
distributions on the right hand side is empty. This cannot occur if the true distribution P0
is consistent with both R and {F kC , F kT }Kk=1, pX . However, the user may impose restrictions
R that are incorrect, i.e., are inconsistent with the true distribution P0, in violation of
Assumption 1 above. We refer to this as model misspecification. It can lead to the bound
parameters evaluated at P0, such as  
R,X
l (P0), being undefined, as discussed in Section 5.
One can also derive bounds on the fraction of a subpopulation who benefits. For any k,
denote  l,k and  u,k as the sharp lower and upper bounds on the fraction of subpopulation
k who benefit, given its marginal distributions and the user-defined assumptions:
 R,Xl,k =  
R,X
l,k (F
k
C , F
k
T )
= inf
 
P 0(YT > YC |X = xk) : P 0 on (YC , YT |X = xk) consistent with R, F kC , F kT
 
.
(7)
In the above display, P 0(YC , YT |X = xk) consistent with R means that P 0(YC = yc, YT =
yT |X = xk) = 0 for any pair (yC , yT ) that is excluded by g.
The bound  R,Xu,k is (7) with sup in place of inf. We show in Appendix B that (7) can be
represented as a linear program, similar to (2). As proved in Appendix C,  R,Xl and  
R,X
u
are weighted sums of  R,Xl,k and  
R,X
u,k , with weights equal to pX(xk); i.e.,
 R,Xl =
KX
k=1
 R,Xl,k pX(xk),  
R,X
u =
KX
k=1
 R,Xu,k pX(xk). (8)
4 Bound Estimators
We discuss estimators for the bounds defined in Section 3.3, using data from a randomized
trial with n participants. We make the assumption below on the data generating distribution:
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Assumption 2. (i) For each participant m = 1, . . . , n, her/his potential outcome vector
Vm = (Xm, YC,m, YT,m) is an independent, identically distributed draw from unknown joint
distribution P0. (ii) The treatment assignments, Am, m = 1, .., n, are independent, identi-
cally distributed Bernoulli(✓), and independent of {Vm}nm=1. (iii) The observed data vector
for participant m is (Xm, Am, Ym) where Ym = AmYT,m + (1  Am)YC,m.
Above, (ii) is justified by randomization and we assume the randomization probability
✓ : 0 < ✓ < 1. The equality in (iii) is called the consistency assumption, which connects
potential outcomes (YC , YT ) and the treatment assignment A to the observed outcome Y .
The estimators in Sections 4.1 and 4.2 are for the parameters  R,Xl and  
R,X
u . It is
straightforward to modify these estimators to handle the special cases of bound parameters
that ignore baseline variables and/or have no restrictions.
4.1 Plug-in estimator
Given the user-defined assumptions R, the bound parameters  R,Xl and  R,Xu are functions
of P through the components {F kC , F kT }Kk=1, pX . One may consider plug-in (also called substi-
tution) estimators of these parameters where sample proportions are used in place of these
components. Define the sample proportions
bF kC(i) = Pnm=1 1(Ym  i, Am = 0, Xm = xk)Pn
m=1 1(Am = 0, Xm = xk)
, (9)
bF kT (j) = Pnm=1 1(Ym  j, Am = 1, Xm = xk)Pn
m=1 1(Am = 1, Xm = xk)
, (10)
bpX(xk) = Pnm=1 1(Xm = xk)
n
, (11)
where 1(E) is the indicator function taking value 1 if E occurs and 0 otherwise. De-
fine the corresponding plug-in estimators b R,Xl =  R,Xl ⇣{ bF kC , bF kT }Kk=1, bpX⌘ and b R,Xu =
 R,Xu
⇣
{ bF kC , bF kT }Kk=1, bpX⌘. These estimators are the solutions to the corresponding linear
programs with empirical proportions substituted for {F kC , F kT }Kk=1, pX . Specifically, we have
b R,Xl = KX
k=1
b R,Xl,k bpX(xk), b R,Xu = KX
k=1
b R,Xu,k bpX(xk), where (12)
b R,Xl,k = min
8>>>>><>>>>>:
X
j>i
i,j2L
⇡ki,j :
⇡ki,j   0 for all i, j 2 LPi
i0=1
PL
j=1 ⇡
k
i0,j = bF kC(i) for all i = 1, .., L  1Pj
j0=1
PL
i=1 ⇡
k
i,j0 = bF kT (j) for all j = 1, .., L  1PL
i=1
PL
j=1 ⇡
k
i,j = 1
⇡ki,j = 0 if g(i, j) = 0
9>>>>>=>>>>>;
, (13)
and b R,Xu,k is the solution to the corresponding maximization problem, for each k.
If support restrictions are made, the above estimators can be inconsistent even when the
support restrictions are true. These estimators may be undefined (i.e., no joint distribution
8
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is both consistent with the restrictions and the empirical marginal distributions within strata
of the baseline variable), with non-negligible probability, for large n. As a simple example,
consider the case where there is no baseline variable, the outcome is binary (failure = 1,
success = 2), and the true, unknown joint distribution P0 on (YC , YT ) satisfies the null
hypothesis of no individual treatment e↵ect, i.e., P0(YC = YT ) = 1. Then the true marginals
satisfy P0(YC = j) = P0(YT = j) for each j 2 {1, 2}. Let the user-defined assumptions R
represent no harm, i.e., the event (YC = 2, YT = 1) is assumed to have probability 0. This
set of restrictions R is consistent with P0. There is only one joint distribution on (YC , YT )
consistent with R and the marginal distributions FC , FT of P0, i.e., P0 itself. Equivalently,
only one matrix (the true JDPO) satisfies the constraints in (2). Therefore, the upper and
lower bound parameters at P0 satisfy ( Rl , 
R
u ) = (0, 0).
The plug-in estimators of these bounds are undefined with probability approximately
1/2, for large sample size n when the randomization probability ✓ = 1/2. The reason
is that if bpC(2) > bpT (2), then no joint distribution on (YC , YT ) is consistent with both the
marginal distributions bFC , bFT and R; in this case, b Rl and b Ru are undefined. The probability
P0(bpC(2) > bpT (2)) converges to 12 as n goes to infinity (Appendix D), implying that b Rl andb Ru are undefined with probability approximately 1/2 even for large sample sizes n.
In general, the plug-in estimators b R,Xl and b R,Xu may fail to converge in probability in
“boundary” cases, i.e., when there is some k for which the linear programs for  R,Xl,k and
 R,Xu,k are feasible but an arbitrarily small perturbation of F
k
C and F
k
T would make them
infeasible. Thus, tiny deviations of bF kC and bF kT , from F kC and F kT , can make (13) and the
corresponding maximization problem infeasible. This causes b R,Xl and b R,Xu to be undefined
with nonzero probability at arbitrarily large n. Boundary cases can only occur if restrictions
R are made. They can occur under the null hypothesis of no individual treatment e↵ect
and the no harm assumption, so they are of practical relevance. In some (but certainly not
all) trials, it can be a reasonable assumption that the treatment does not cause harm, so
this restriction is practically relevant for analyzing such trials. One solution that can handle
boundary cases is to ignore the restriction and estimate ( l, u) or ( Xl , 
X
u ). However, this
may be a waste of valuable subject matter knowledge because a restriction can substantially
improve the bounds, e.g., in the above example ( Rl , 
R
u ) = (0, 0), while ( l, u) = (0, 0.5).
To address this, we propose an alternative estimator that can incorporate restrictions and
that is consistent even in boundary cases.
4.2 Proposed estimator
We propose an estimator that relaxes the constraints regarding bF kC and bF kT in (13) to prevent
cases as above where no joint distribution is consistent with R and all bF kC and bF kT . We define
our estimators,  
R,X
l and  
R,X
u , as:
 
R,X
l =
KX
k=1
 
R,X
l,k bpX(xk),  R,Xu = KX
k=1
 
R,X
u,k bpX(xk), (14)
9
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where  
R,X
l,k is computed by solving the following sequence of linear programs:
✏k = min
8>>>>>><>>>>>>:
✏k   0 :
⇡ki,j   0 for all i, j 2 L   Pii0=1PLj=1 ⇡ki0,j   bF kC(i)     ✏k for all i = 1, .., L  1   Pjj0=1PLi=1 ⇡ki,j0   bF kT (j)     ✏k for all j = 1, .., L  1PL
i=1
PL
j=1 ⇡
k
i,j = 1
⇡ki,j = 0 if g(i, j) = 0
9>>>>>>=>>>>>>;
, (15)
 
R,X
l,k = min
8>>>>>><>>>>>>:
X
j>i
i,j2L
⇡ki,j :
⇡ki,j   0 for all i, j 2 L   Pii0=1PLj=1 ⇡ki0,j   bF kC(i)     ✏k for all i = 1, .., L  1   Pjj0=1PLi=1 ⇡ki,j0   bF kT (j)     ✏k for all j = 1, .., L  1PL
i=1
PL
j=1 ⇡
k
i,j = 1
⇡ki,j = 0 if g(i, j) = 0
9>>>>>>=>>>>>>;
.(16)
The estimator  
R,X
u,k is (16), with max in place of min. In (16), ✏k is used to relax the
constraints regarding bF kC and bF kT . For a matrix to satisfy the constraints in (16), its marginal
distribution functions do not need to match bF kC and bF kT , but they must be within ✏k of bF kC(i)
and bF kT (j) for all i, j = 1, .., L  1. Referring to (15), ✏k is the minimum value such that the
linear programs for  
R,X
l,k and  
R,X
u,k are feasible. If b R,Xl,k and b R,Xu,k are well-defined, we have
✏k = 0, so  
R,X
l,k = b R,Xl,k and  R,Xu,k = b R,Xu,k . If b R,Xl,k and b R,Xu,k are undefined, ✏k > 0 and
 
R,X
l,k and  
R,X
u,k are well-defined.
For any k, (15) and (16) are linear programs because the absolute value statements can
each be converted to a pair of linear inequalities. We provide R and MATLAB software that
uses linear programming to compute  
R,X
l and  
R,X
u .
The estimator  
X
l for the lower bound with no restrictions  
X
l is a special case of  
R,X
l ,
where R corresponds to the function g that maps all pairs (i, j) to 1. The estimator  Rl
for the lower bound with no baseline variable  Rl is defined as the solution to (16) where
⇡ki,j, bF kC , bF kT , ✏k, ✏k are replaced by ⇡i,j, bFC , bFT , ✏, ✏, respectively, throughout (15)-(16). Here,bFC , bFT are defined as (9)-(10), except with Xm = xk omitted. The estimator  l for the lower
bound  l is obtained by applying both of the above modifications. The corresponding upper
bound estimators are obtained similarly.
As proved in Appendix E,  
R,X
l and  
R,X
u are consistent, i.e., they converge to the
corresponding bound parameters as n goes to infinity. By a similar proof, it can be shown
that the estimators which ignore baseline variables and/or have no restriction are consistent.
Theorem 2. For any X andR, if P0 is consistent withR, then  R,Xl and  R,Xu are consistent
estimators of  R,Xl (P0) and  
R,X
u (P0), respectively.
Theorems 1 and 2 imply that if P0 is consistent with R, then the probability limits of the
estimators  
R,X
l , 
R
l , 
X
l , l satisfy the inequalities in Theorem 1. This means that including
10
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a baseline variable or restriction can only improve (or leave unchanged) the limiting value
of the bound estimators, leading to larger or equal lower bounds and smaller or equal upper
bounds. However, at a given sample size, neither the plug-in estimators from Section 4.1 nor
the above estimators are guaranteed to satisfy the corresponding inequalities in Theorem 1.
5 MISTIE Application using Bound Estimators from
Section 4.2
Using data from the MISTIE II trial, we estimate bounds on the fraction of intracerebral
hemorrhage patients who benefit from image-guided minimally invasive surgery (treatment),
relative to standard medical care (control), with respect to 30-day mRS score, 180-day mRS
score, and reduction in clot volume. We use the estimators from Section 4.2. Tables 1-3 in
the Supplementary Materials give all bound estimates. The Supplementary Materials can
be found at the end of this document.
5.1 30- and 180-day mRS Scores
For both 30- and 180-day mRS scores, four types of sharp lower/upper bounds are estimated:
(i) no baseline variables or user-defined assumptions, (ii) user-defined assumption only, (iii)
baseline variable only, (iv) both a user-defined assumption and a baseline variable. These
correspond to bound parameters ( l, u),( Rl , 
R
u ),( 
X
l , 
X
u ),( 
R,X
l , 
R,X
u ), respectively, as
defined in Section 3.3.
The user-defined assumptions we consider are Benefit  d levels and Harm  d levels.
The value d is varied from 1 to 5 for the former, and 0 to 5 for the latter. (d is not set to 0
for the former since that restriction would imply the fraction who benefit is 0). The baseline
variable is stroke severity, where a stroke is classified as non-severe if the baseline NIHSS
score  20 and severe otherwise (Kreutzer et al., 2011).
The bound estimators are those from Section 4.2. When estimating bounds for a given
outcome (e.g., 180-day mRS), we exclude participants who are missing that outcome; for
both mRS outcomes, we exclude the single patient with missing baseline NIHSS score. The
resulting sample sizes are 53 treatment and 39 control participants for 30-day mRS score,
and 52 treatment and 37 control participants for 180-day mRS score. To estimate bounds (i)
and (ii), we use the empirical distributions of the mRS scores under treatment and control,
shown in the top panel of Figure 2. To estimate bounds (iii) and (iv), we use the empirical
distributions after stratifying by subpopulation, shown in the bottom two panels of Figure 2.
The proportion in each subpopulation is estimated by the corresponding sample proportion
of MISTIE II participants (after excluding participants as described above). We discuss
methods that adjust for missing outcomes in Section 7, which is an area of future research.
Figures 3a and 3b present the bound estimates for 30- and 180-day mRS scores, respec-
tively. With neither user-defined assumptions nor baseline variable, the pair of estimated
bounds
⇥
 l, u
⇤
on the proportion who benefit is [0.07,0.61] for 30-day mRS, and [0.10,0.73]
for 180-day mRS. The widths of these estimated bounds, i.e., the di↵erence between the
upper and lower bound estimates, are 0.54 and 0.63, respectively. Imposing user-defined
assumptions can narrow the width of the estimated bounds. For the 180-day outcome, the
11
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width narrows by 0.17 under Benefit  1, 0.31 under Harm  1, and 0.55 under no harm,
relative to no user-defined assumptions. These reductions are absolute di↵erences in widths,
as is the case throughout the paper.
Incorporating the baseline variable narrows the width of the estimated bounds by 0.19
for 30-day mRS, and 0.12 for 180-day mRS (under no restrictions). However, the baseline
variable does not have a large impact in every case. Under the restriction R = {Harm  2},
it narrows the width only by 0.02 for 180-day mRS score; also, the upper bound estimate
with the baseline variable ( 
R,X
u = 0.63) is slightly above that without the baseline variable
( 
R
u = 0.62). This can occur since, as mentioned in Section 4.2, the bound estimators need
not obey the corresponding inequalities in Theorem 1.
In Figure 3, there are five sets of restrictions under which ✏¯ > 0 or at least one ✏¯k > 0,
indicating the marginal distribution constraints were relaxed in the bound estimators. We
point out two features. First, these bound estimates may not be contained within the interval
formed by estimates under a less stringent restriction. For example, for 30-day mRS, the
lower bound estimate under R = {no harm} is  Rl = 0.03, which is below the lower bound
estimate  
R0
l = 0.07 under the weaker restriction R0 = {Harm  1}. This behavior is either
due to a boundary case (see Section 4), small sample performance of the estimator, or the
data generating distribution not satisfying the no harm assumption. In the third case, the
bound estimators may be inconsistent.
Second, for a given restriction, an upper bound estimate can be much larger, or a lower
bound estimate much smaller, with the baseline variable than without it. For example, under
the restriction R = {no harm}, the upper bound estimate without the baseline variable is
 
R
u = 0.18, while the corresponding estimate with the baseline variable is  
R,X
u = 0.50, for
the 180-day mRS outcome. By Theorem 1, the true upper bound can only decrease or stay
the same with the addition of a baseline variable, i.e.,  Ru (P0)    R,Xu (P0), if the user-defined
assumptions are true (i.e., if P0 consistent with R). One possible cause for the behavior we
observe is that the no harm assumption is false, in which case  Ru could be well-defined while
 R,Xu is not. Then  
R
u could be much smaller than  
R,X
u , even at large sample sizes. Such a
discrepancy could be used as a test of the assumptions R, which is an area of future research.
In addition to the fraction who benefit for the total population, one may be interested
in the fraction for a specific subpopulation, i.e., P (YT > YC |X = xk). Here, X represents
baseline stroke severity, with x1=nonsevere and x2=severe. Figure 4 presents the estimated
bounds for each subpopulation, i.e.,
h
 
R,X
l,k , 
R,X
u,k
i
for k = 1, 2. Without user-defined assump-
tions, the estimated bounds are [0.04, 0.41] for the non-severe subpopulation, and [0.26, 0.60]
for the severe subpopulation, for 30-day mRS score. For 180-day mRS score, the estimated
bounds are [0.01, 0.59] for the non-severe subpopulation, and [0.22, 0.68] for the severe
subpopulation. Imposing user-defined assumptions can improve the bounds, which can be
reflected in the bound estimates. For example, under Harm  1, the estimated bounds of the
non-severe subpopulation are [0.04, 0.26] for 30-day mRS score. Confidence interval widths
(described in Section 6) will generally be wider than for the bounds on the total population,
due to smaller sample sizes.
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5.2 Reduction in Clot Volume
Another outcome in MISTIE II is reduction in clot volume (RICV), the di↵erence between
clot volume at baseline and end of treatment, as defined in Mould et al. (2013). RICV is
a continuous variable in units of mL. In MISTIE II, the observed RICV range was [-2.57,
75.45] mL under treatment, and [-14.86, 12.01] mL under control. To apply our method,
we discretize RICV into an ordinal variable with six levels. For a reduction of y mL, the
corresponding level is 1 if y < -5, 2 if -5  y < 0, 3 if 0  y < 5, 4 if 5  y < 10, 5 if
10  y < 15, and 6 if y   15. The ordinal approximation may not reflect small benefits (i.e.,
individual benefits within a category), but does capture benefits of large enough magnitude
to transition between categories. Below, we refer to the ordinal variable as RICV.
Since higher levels correspond to better outcomes, the fraction who benefit is the fraction
who would have a higher RICV under treatment than under control. We estimate the same
types of sharp bounds (i)-(iv) as in Section 5.1. The restrictions R that we consider are
Benefit  d and Harm  d. The value d is varied from 1 to 4 for the former, and 0 to 4 for
the latter. The baseline variable is an indicator of the baseline clot volume being above or
below the median baseline clot volume of the MISTIE II participants (43.2 mL).
All MISTIE II participants are included, and there are no missing data for RICV or
the baseline variable. The sample sizes for the RICV analysis are 54 treatment and 42
control participants. To estimate bounds (i) and (ii), we use the empirical distributions of
the RICV’s under treatment and control, shown in the top panel of Figure 5. The empirical
distribution for treatment first-order stochastically dominates that for control. While all
control patients had RICV 5 or less, 74% of treatment patients had RICV 6. This suggests
that treatment has a major e↵ect on RICV. To estimate bounds (iii) and (iv), we use the
empirical distributions after stratifying by subpopulation, shown in the bottom two panels
of Figure 5. There is also stochastic dominance of treatment within each subpopulation.
Figure 6a presents the estimated bounds on the fraction who benefit for the total pop-
ulation. With neither the baseline variable nor restrictions, the estimated bounds on the
proportion who benefit are [0.82, 0.99]. As in the mRS results, the baseline variable and
user-defined assumptions narrow the estimated bounds for RICV. For example, with the
baseline variable and the assumption of Benefit  4, the width of the estimated bounds nar-
rows by 0.05. This improvement may seem small, but is substantial as a proportion of the
estimated bound width when neither assumptions nor the baseline variable is used (0.17).
The restrictions on harm are not included on the x-axis because the estimated bounds
are the same as under no assumptions. This is because there are matrices that satisfy the no
harm assumption, are consistent with the empirical marginal distributions, and have fraction
who benefit equal to 0.82 or 0.99. The bound estimates for Benefit  1 and Benefit  2 are
much wider than for the less stringent restrictions. In these cases, large values of ✏ and ✏k
(ranging from 0.22 to 0.62) occur. Large values of ✏ or ✏k raise doubts about the validity of
the user-defined assumptions; it is an area of future work to construct formal hypothesis tests
for this problem, to determine with high confidence whether a large observed value of ✏ or ✏k
can be explained by chance variation or is due to violations of the user-defined assumptions.
Bounds under false assumptions are not guaranteed to contain the true fraction who benefit.
Finally, we estimate bounds on the fraction who benefit for each subpopulation. The
estimates are shown in Figure 6b. Without user-defined assumptions, the estimated bounds
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on the proportion who benefit are [0.81, 0.96] for those with low baseline clot volume (< 43.2
mL), and [0.86, 1.00] for those with high baseline clot volume (  43.2 mL).
6 Simulation Studies
We conduct simulation studies to evaluate the bias and standard error of the estimators from
Section 4.2. We also study the performance of n- and m-out-of-n bootstrap in constructing
95% confidence intervals (CI’s) for the bounds.
Two outcomes are separately considered: RICV and a binary outcome. In both cases, no
baseline variable is used. For RICV, the data generating distributions under treatment and
control are set to be the empirical distributions in MISTIE II, shown in the top panel of Figure
5. No user-defined assumptions are made. The bound parameters are ( l, u) = (0.82, 0.99).
For the binary outcome, the data generating distribution is P0(YT = y) = P0(YC = y) =
1
2 for
y 2 {1, 2}. We consider the cases where no assumptions are made, and where the no harm
assumption is made. The bound parameters are ( l, u) = (0, 0.5) and ( Rl , 
R
u ) = (0, 0),
where R = {no harm}. We refer to the three cases as RICV, binary (no restrictions), and
binary (no harm).
For each case, we simulate 10,000 randomized trials each with n participants (n2 in treat-
ment, n2 in control). We consider n = 100, 500, and 1000, respectively. In each simulated
trial, the estimators from Section 4.2 are computed. Also, we compute a two-sided 95% CI
for the lower bound and a separate two-sided 95% CI for the upper bound, using n- and
m-out-of-n bootstrap. For n-bootstrap (percentile method), we generate 10,000 replicated
data sets by resampling n participants, with replacement, from the simulated trial data.
For m-out-of-n bootstrap, the procedure is the same, except each of the 10,000 replicated
datasets is generated by sampling m participants with replacement, where m  n. The value
m is chosen using the procedure in Section 2 of Bickel and Sakov (2008), setting tuning pa-
rameter q = 0.95 to create a list of candidate values and generating 5,000 replicated datasets
for each candidate value. We implement m-out-of-n bootstrap since it can in some cases
have better asymptotic properties than n-bootstrap (Bickel and Sakov, 2008).
Table 1a shows the estimated bias and standard error of the bound estimators, as a
function of the trial size n. Bias is negligible in the RICV case. For the binary outcome, the
magnitude of bias is approximately 0.04 at n = 100, 0.02 at n = 500, and 0.01 at n = 1000.
Bias corrections have been developed for bound estimators involving continuous outcomes
(Fan and Park, 2009; Kim, 2014). An area of future work is to develop a bias correction for
our estimator.
Table 1b shows the empirical coverage probability of the nominal 95% CI’s constructed
using n- and m-out-of-n bootstrap, as a function of trial size n. For the binary outcome, the
CI’s tend to have overcoverage compared to the nominal value of 95%. Coverage is ⇡ 99%
for m-out-of-n bootstrap, and ⇡ 97% for n-bootstrap. One exception is the CI’s for  u in the
binary (no restriction) case. In this case, both techniques under-cover  u, with m-out-of-n
bootstrap at ⇡ 93% coverage and n-bootstrap at ⇡ 90% coverage, even at n = 1000. For
RICV, empirical coverage is generally close to the nominal coverage. An exception is that m-
out-of-n and n-bootstrap have empirical coverage rates of only 84% and 82%, respectively,
for  u, when n = 100. In Table 1b, m-out-of-n bootstrap generally has higher empirical
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coverage probability than n-bootstrap.
Fan and Park (2010) implement the n- and m-out-of-n bootstrap at sample sizes from
1000 to 4000. In their simulations, the coverage probabilities of the two techniques are
similar and approximately the nominal coverage. In our simulations, the coverage rates of
the two approaches are less similar and we observe some undercoverage even at n = 1000.
In Table 1b, average CI width is slightly higher for m-out-of-n bootstrap than for n-
bootstrap. The average CI width also varies by case and by the bound being considered.
For example, in the RICV case, average CI width tends to be smaller for the upper bound
than for the lower bound.
Our results show that n- and m-out-of-n bootstrap can be unreliable when n = 100.
However, m-out-of-n bootstrap has empirical coverage rates above or only slightly below the
nominal rate when n = 500 or 1000.
7 Discussion
In the MISTIE application, the interval corresponding to the lower and upper bound esti-
mates is narrow for RICV, and wide for both the 30- and 180-day mRS scores. This gives a
proof of concept example showing that depending on the outcome, the proposed estimator
of the fraction who benefit can be informative.
Incorporating a prognostic baseline variable or user-defined assumption can improve the
bounds. Open problems are to identify which baseline variables are most e↵ective at nar-
rowing the bounds and to determine the optimal number of subpopulations on which to
stratify, based on the trial size. If more strata are used, the bounds may become narrower,
but estimation of F kC and F
k
T (k = 1, .., K) is less precise. We seek a balance between narrow
bounds and low variance.
Our data application shows that restrictions on benefit and harm can improve the bound
estimates. For example, for 180-day mRS, we have ( l, u) = (0.10, 0.73), in contrast to
( 
R
l , 
R)
u = (0.10, 0.18) when R = {no harm}. The latter bound estimates, though highly
informative due to the lower and upper bound estimators being much closer together, are
only valid if the no harm assumption is true (which needs to be based on subject matter
knowledge). This can be appropriate in some clinical settings but not in others. It is possible
to generate evidence against the restriction being true by considering the estimator ✏¯k, which
in our application raises substantial doubts. Though certain deviations from the restrictions
may be detectable, other types of deviations may not be. One may view the bound estimators
under nested sets of more stringent restrictions as being a sensitivity analysis to examine
how much information on the fraction who benefit would result under di↵erent types of
assumptions on harm/benefit.
We impose restrictions on benefit and harm separately, but they can also be imposed
jointly. Since linear programming can incorporate any linear equality or inequality con-
straints on the ⇡i,j’s, it is possible to explore, e.g., the e↵ects of other types of assumptions
than support restrictions, such as monotonicity of ⇡i,j’s (e.g., ⇡3,1  ⇡3,2).
Our simulation results show that n- and m-out-of-n bootstrap can have undercoverage
when n = 100. An area of future work is to identify an alternative method which can achieve
the nominal coverage at n = 100.
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It is possible to extend our approach to handle missing outcomes, such as by using
double robust estimators of the marginal distributions instead of the empirical marginal
distributions ignoring missing outcomes. Under the missing at random assumption, one could
use estimators of the marginal distribution functions that adjust for baseline confounders,
e.g., using methods of Diaz et al. (2015).
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Figures and Tables
(a) Under no assumptions
YT
1 2 3 4 5 6 7
YC
1 ⇡1,1 ⇡1,2 ⇡1,3 ⇡1,4 ⇡1,5 ⇡1,6 ⇡1,7 pC(1)
2 ⇡2,1 ⇡2,2 ⇡2,3 ⇡2,4 ⇡2,5 ⇡2,6 ⇡2,7 pC(2)
3 ⇡3,1 ⇡3,2 ⇡3,3 ⇡3,4 ⇡3,5 ⇡3,6 ⇡3,7 pC(3)
4 ⇡4,1 ⇡4,2 ⇡4,3 ⇡4,4 ⇡4,5 ⇡4,6 ⇡4,7 pC(4)
5 ⇡5,1 ⇡5,2 ⇡5,3 ⇡5,4 ⇡5,5 ⇡5,6 ⇡5,7 pC(5)
6 ⇡6,1 ⇡6,2 ⇡6,3 ⇡6,4 ⇡6,5 ⇡6,6 ⇡6,7 pC(6)
7 ⇡7,1 ⇡7,2 ⇡7,3 ⇡7,4 ⇡7,5 ⇡7,6 ⇡7,7 pC(7)
pT (1) pT (2) pT (3) pT (4) pT (5) pT (6) pT (7)
(b) Under restriction on benefit with d = 3
YT
1 2 3 4 5 6 7
YC
1 ⇡1,1 ⇡1,2 ⇡1,3 ⇡1,4 0 0 0 pC(1)
2 ⇡2,1 ⇡2,2 ⇡2,3 ⇡2,4 ⇡2,5 0 0 pC(2)
3 ⇡3,1 ⇡3,2 ⇡3,3 ⇡3,4 ⇡3,5 ⇡3,6 0 pC(3)
4 ⇡4,1 ⇡4,2 ⇡4,3 ⇡4,4 ⇡4,5 ⇡4,6 ⇡4,7 pC(4)
5 ⇡5,1 ⇡5,2 ⇡5,3 ⇡5,4 ⇡5,5 ⇡5,6 ⇡5,7 pC(5)
6 ⇡6,1 ⇡6,2 ⇡6,3 ⇡6,4 ⇡6,5 ⇡6,6 ⇡6,7 pC(6)
7 ⇡7,1 ⇡7,2 ⇡7,3 ⇡7,4 ⇡7,5 ⇡7,6 ⇡7,7 pC(7)
pT (1) pT (2) pT (3) pT (4) pT (5) pT (6) pT (7)
Figure 1: Joint distribution on the potential outcomes (JDPO). Yellow corresponds to no
individual treatment e↵ect, red to harm, and green to benefit.
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(a) 30-day
1 2 3 4 5 6 7
Total Population
mRS score
0
1 nT = 53 , nC = 39 treatment
control
1 2 3 4 5 6 7
Subpopulation with non−severe stroke
mRS score
0
1 nT = 21 , nC = 18
1 2 3 4 5 6 7
Subpopulation with severe stroke
mRS score
0
1 nT = 32 , nC = 21
(b) 180-day
1 2 3 4 5 6 7
Total Population
mRS score
0
1 nT = 52 , nC = 37 treatment
control
1 2 3 4 5 6 7
Subpopulation with non−severe stroke
mRS score
0
1 nT = 21 , nC = 17
1 2 3 4 5 6 7
Subpopulation with severe stroke
mRS score
0
1 nT = 31 , nC = 20
Figure 2: Empirical probability mass functions of (a) 30-day and (b) 180-day mRS scores
under treatment and control.
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(a) 30-day mRS score
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(b) 180-day mRS score
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Figure 3: Estimated lower and upper bounds (using method from Section 4.2) on the fraction
who benefit, with respect to (a) 30-day and (b) 180-day mRS score. Each bar ranges from
the lower to upper bound estimate. A bar is grey if the baseline variable is not used, and
black otherwise. The user-defined assumption imposed, if any, is indicated on the x-axis.
For conciseness, restrictions were excluded from these figures if their corresponding grey and
black bars were identical to those under no user-defined assumptions. For grey bars, the value
of ✏ is listed above the bar, if it is nonzero. For black bars, ✏=* indicates that one or more
of the ✏k’s is nonzero.
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(b) 180-day mRS score
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Figure 4: Estimated lower and upper bounds (using method from Section 4.2) on the fraction
who benefit, with respect to (a) 30-day and (b) 180-day mRS score, for each subpopulation.
For bars corresponding to the subpopulation with non-severe stroke, the value of ✏1 is listed
above the bar, if nonzero. For bars corresponding to the subpopulation with severe stroke, the
value of ✏2 is listed above the bar, if nonzero.
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Total Population
RICV
0
1 nT = 54 , nC = 42 treatment
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1 2 3 4 5 6
Subpopulation with low baseline clot volume
RICV
0
1 nT = 26 , nC = 22
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Subpopulation with high baseline clot volume
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1 nT = 28 , nC = 20
Figure 5: Empirical probability mass functions of RICV, under treatment and control. The
empirical distributions are presented for the total population, and for each subpopulation
(i.e., low or high baseline clot volume). RICV is a discretization of continuous reduction in
clot volume, y mL, as: 1 if y < -5, 2 if -5  y < 0, 3 if 0  y < 5, 4 if 5  y < 10, 5 if
10  y < 15, and 6 if y   15.
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(a) Bounds for Total Population
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(b) Bounds for Each Subpopulation
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Figure 6: Estimated bounds on the fraction who benefit, with respect to RICV. (a) gives
the estimated bounds for the total population and (b) gives the estimated bounds separately
for each subpopulation (i.e., low or high baseline clot volume).
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Supplementary Materials
Appendix A: Proof of Theorem 1
Theorem 1. Consider any user-defined assumptions R, baseline variable X, and joint dis-
tribution P on (X, YC , YT ) that is consistent with R. Then we have  R,Xl   max{ Xl , Rl }
and min{ Xl , Rl }    l, where each bound parameter is evaluated at P .
Proof. Let FC , FT , and pX be the marginal distributions of YC , YT , and X, respectively,
under P . For each k = 1, .., K, let F kC and F
k
T be the conditional distributions of YC and YT
given X = xk, under P . We have the following:
 R,Xl = inf
 
P 0(YT > YC) : P 0 on (X, YC , YT ) consistent with R, {F kC , F kT }Kk=1, pX
 
(1)
  inf  P 0(YT > YC) : P 0 on (X, YC , YT ) consistent with {F kC , F kT }Kk=1, pX (2)
=  Xl .
 Xl = inf
 
P 0(YT > YC) : P 0 on (X, YC , YT ) consistent with {F kC , F kT }Kk=1, pX
 
(3)
  inf {P 0(YT > YC) : P 0 on (X, YC , YT ) consistent with FC , FT} (4)
=  l.
 R,Xl = inf
 
P 0(YT > YC) : P 0 on (X, YC , YT ) consistent with R, {F kC , F kT }Kk=1, pX
 
(5)
  inf {P 0(YT > YC) : P 0 on (X, YC , YT ) consistent with R, FC , FT} (6)
=  Rl .
 Rl = inf {P 0(YT > YC) : P 0 on (X, YC , YT ) consistent with R, FC , FT} (7)
  inf {P 0(YT > YC) : P 0 on (X, YC , YT ) consistent with FC , FT} (8)
=  l.
Notice that all of these bound parameters are well-defined since P is consistent with
FC ,FT ,{F kC , F kT }Kk=1, pX , and R. Inequalities (2) and (6) hold because the constraint that P 0
is consistent with R has been removed on the right sides, so the inf is being taken over an
increased set leading to smaller or equal value. Inequalities (4) and (8) hold because the
inf is being taken over an increased set on the right sides, since any P 0 consistent with all
{F kC , F kT }Kk=1, pX is also consistent with FC , FT , as shown below:
1
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If P 0 consistent with all {F kC , F kT }Kk=1, pX (which are the marginal distributions corre-
sponding to P ), then for any y,
P 0(YC  y) =
KX
k=1
P 0(YC  y|X = xk)P 0(X = xk) (9)
=
KX
k=1
F kC(y)pX(xk) (10)
=
KX
k=1
P (YC  y|X = xk)P (X = xk) (11)
= P (YC  y) (12)
= FC(y), (13)
so P 0 is consistent with FC . Using an analogous proof, it can be shown that P 0 is consistent
with FT .
Since  R,Xl    Xl and  R,Xl    Rl , we have  R,Xl   max{ Xl , Rl }. Since  Xl    l and
 Rl    l, we have min{ Xl , Rl }    l.
2
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Appendix B: Representing  R,Xl,k and  
R,X
u,k as Solutions to Linear
Programs
For any k, the lower bound  R,Xl,k is the solution to a linear program because:
 R,Xl,k = min
8>>>>><>>>>>:
X
j>i
i,j2L
⇡ki,j :
⇡ki,j   0 for all i, j 2 LPi
i0=1
PL
j=1 ⇡
k
i0,j = F
k
C(i) for all i = 1, .., L  1Pj
j0=1
PL
i=1 ⇡
k
i,j0 = F
k
T (j) for all j = 1, .., L  1PL
i=1
PL
j=1 ⇡
k
i,j = 1
⇡ki,j = 0 if g(i, j) = 0
9>>>>>=>>>>>;
, (14)
where ⇡ki,j = P
0(YC = i, YT = j|X = xk) for any i, j in L. The upper bound  R,Xu,k is (14),
with max in place of min, so it is also a solution to a linear program.
3
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Appendix C: Proof of (8)
Consider any user-defined assumption R, baseline variable X, and joint distribution P on
(X, YC , YT ) that is consistent with R. Then we have
 R,Xl =
KX
k=1
 R,Xl,k pX(xk),  
R,X
u =
KX
k=1
 R,Xu,k pX(xk),
where each parameter is evaluated at P .
Proof. The bounds  R,Xl and  
R,X
u are defined as:
 R,Xl = inf
 
P 0(YT > YC) : P 0 on (X, YC , YT ) consistent with R, {F kC , F kT }Kk=1, pX
 
,
 R,Xu = sup
 
P 0(YT > YC) : P 0 on (X, YC , YT ) consistent with R, {F kC , F kT }Kk=1, pX
 
,
where F kC(y) = P (YC  y|X = xk) and F kT (y) = P (YT  y|X = xk) for any y and k, and
pX(xk) = P (X = xk) for any k. For each k, we have that:
 R,Xl,k = inf
 
P 0(YT > YC |X = xk) : P 0 on (YC , YT |X = xk) consistent with R, F kC , F kT
 
,
 R,Xu,k = sup
 
P 0(YT > YC |X = xk) : P 0 on (YC , YT |X = xk) consistent with R, F kC , F kT
 
,
Since  R,Xl ,  
R,X
u , { R,Xl,k }Kk=1, and { R,Xu,k }Kk=1 are solutions to linear programs, inf can be
replaced with min, and sup with max in the four definitions above.
We now show that
PK
k=1  
R,X
l,k pX(xk) and
PK
k=1  
R,X
u,k pX(xk) are in the set 
P 0(YT > YC) : P 0 on (X, YC , YT ) consistent with R, {F kC , F kT }Kk=1, pX
 
. (15)
That is, there exist joint distributions Pl and Pu on (X, YC , YT ) that (i) are consistent with
R, (ii) are consistent with {F kC , F kT }Kk=1 and pX , and (iii) Pl(YT > YC) =
PK
k=1  
R,X
l,k pX(xk),
Pu(YT > YC) =
PK
k=1  
R,X
u,k pX(xk). For any k, by the definition of  
R,X
l,k , there exists a
joint distribution Pl,k on (YC , YT |X = xk) that is consistent with R,F kC , and F kT , and sat-
isfies Pl,k(YT > YC |X = xk) =  R,Xl,k . Define Pl as follows. Let Pl(YC , YT |X = xk) =
Pl,k(YC , YT |X = xk) for each k. Let Pl(X = xk) = pX(xk) for each k. It follows that
Pl satisfies (i) and (ii). Also, Pl(YT > YC) =
PK
k=1 Pl(YT > YC |X = xk)Pl(X = xk) =PK
k=1  
R,X
l,k pX(xk). The joint distribution Pu can be defined analogously as Pl. Thus,PK
k=1  
R,X
l,k pX(xk) and
PK
k=1  
R,X
u,k pX(xk) are in (15).
Now it remains to show that
PK
k=1  
R,X
l,k pX(xk) and
PK
k=1  
R,X
u,k pX(xk) are the mini-
mum and maximum of (15), respectively. We do a proof by contradiction. Suppose that
the minimum of (15) is smaller than
PK
k=1  
R,X
l,k pX(xk). This would imply that, for some
k, there exists a distribution P 0 on (YC , YT |X = xk) that is consistent with R, F kC , F kT
and with P 0(YT > YC |X = xk) <  R,Xl,k . However, this contradicts the definition of
 R,Xl,k . Thus,
PK
k=1  
R,X
l,k pX(xk) is the minimum of (15). It can be shown analogously thatPK
k=1  
R,X
u,k pX(xk) is the maximum of (15). We conclude that
 R,Xl =
KX
k=1
 R,Xl,k pX(xk),  
R,X
u =
KX
k=1
 R,Xu,k pX(xk).
4
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Appendix D: Proof that limn!1 P0(bpC(2) > bpT (2)) = 12 for the
Example in Section 4.1
Proof. Consider any n in N. There are three possible cases: bpC(2) > bpT (2), bpC(2) < bpT (2),
or bpC(2) = bpT (2). Since ✓ = 12 and pC(2) = pT (2), P0(bpC(2) > bpT (2)) = P0(bpC(2) < bpT (2)).
Therefore,
P0(bpC(2) > bpT (2)) = 1  P0(bpC(2) = bpT (2))
2
.
Now let n go to infinity. Then we have
lim
n!1
P0(bpC(2) > bpT (2)) = lim
n!1
1  P0(bpC(2) = bpT (2))
2
=
1
2
.
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Appendix E: Proof of Theorem 2
In the proofs of Theorem 2 and Lemma 2, the following notation is used. Limits are taken
as n ! 1. For example, p! signifies convergence in probability as n ! 1. Define 1E
to be a random variable which takes the value 1 if the event E occurs, and 0 otherwise.
Generally, define [zi,j]Li=1 = [z1,j, z2,j, ..., zL,j] and [zi,j]
L
j=1 = [zi,1, zi,2, ..., zi,L]. Also, define
kyk2 =
qPM
i=1 y
2
i , where y = (y1, y2, .., yM)
T .
Theorem 2. For any X andR, if P0 is consistent withR, then  R,Xl and  R,Xu are consistent
estimators of  R,Xl (P0) and  
R,X
u (P0), respectively.
Proof. Consider any X and R. Let P0 be any joint distribution on (X, YC , YT ) consistent
with R. Suppose that Assumption 2 holds. We will show that  R,Xl p!  R,Xl (P0) and
 
R,X
u
p!  R,Xu (P0) as n!1. Below, we suppress the dependence of the bound parameters
on P0 for conciseness. Let {F kC , F kT }Kk=1, pX be the marginal distributions corresponding to
P0.
The structure of the proof is as follows. We show that: (I) bpX(xk) p! pX(xk) for each
k; and (II)  
R,X
l,k
p!  R,Xl,k and  
R,X
u,k
p!  R,Xu,k for each k. By Slutsky’s Theorem, (I) and
(II) imply that  
R,X
l
p!  R,Xl and  
R,X
u
p!  R,Xu . By the Weak Law of Large Numbers, (I)
follows from Assumption 2(i). We must show that (II) also holds.
Choose any k = 1, .., K. We now prove that  
R,X
l,k
p!  R,Xl,k . Fix n 2 N. Consider the
following linear program, which we refer to as LP:
min
x
cTx, subject to Ax  b, x   0.
Define x and c as:
x =
⇥
[⇡ki,1]
L
i=1, [⇡
k
i,2]
L
i=1, . . . , [⇡
k
i,L]
L
i=1
⇤T
,
cT =
⇥
[11>i]Li=1, [12>i]
L
i=1, . . . , [1L>i]
L
i=1
⇤
,
where 1j>i takes the value 1 if j > i and 0 otherwise. Define A as the matrix that satisfies:
Ax =
P
g(i,j)=0 ⇡
k
i,j,
PL
i=1
PL
j=1 ⇡
k
i,j,  
PL
i=1
PL
j=1 ⇡
k
i,j, [
Pi
i0=1
PL
j=1 ⇡
k
i0,j]
L 1
i=1 ,
[ Pii0=1PLj=1 ⇡ki0,j]L 1i=1 , [Pjj0=1PLi=1 ⇡ki,j0 ]L 1j=1 , [ Pjj0=1PLi=1 ⇡ki,j0 ]L 1j=1  T .
Let f(b) denote the optimal value of the linear program as a function of b. Define:
b⇤ =
h
0, 1,  1, ⇥F kC(i)⇤L 1i=1 , ⇥ F kC(i)⇤L 1i=1 , ⇥F kT (j)⇤L 1j=1 , ⇥ F kT (j)⇤L 1j=1 iT ;
bn =

0, 1,  1,
h bF kC(i) + ✏kiL 1
i=1
,
h
  bF kC(i) + ✏kiL 1
i=1
,h bF kT (j) + ✏kiL 1
j=1
,
h
  bF kT (j) + ✏kiL 1
j=1
 T
.
6
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When b = bn, LP is equivalent to the linear program for  
R,X
l,k . Therefore, f(b
n) =  
R,X
l,k  1.
When b = b⇤, LP is equivalent to the linear program for  R,Xl,k . Therefore, f(b
⇤) =  R,Xl,k  1.
(LP is feasible when b = b⇤ since P0 is consistent with R.) By Lemma 1 below, there exists
a constant C > 0 such that |f(b) f(b⇤)|  Ckb  b⇤k2 for any b with f(b) <1. This means
that |f(bn)  f(b⇤)|  Ckbn   b⇤k2. Choose any ⌘ > 0. Then
P0(| R,Xl,k    R,Xl,k | > ⌘) = P0(|f(bn)  f(b⇤)| > ⌘)
 P0
⇣
kbn   b⇤k2 > ⌘
C
⌘
.
By Lemma 2 below, ✏k
p! 0. Also, bF kC(i) p! F kC(i) and bF kT (j) p! F kT (j) for all i, j = 1, .., L 1
by the Weak Law of Large Numbers. By Slutsky’s Theorem, bF kC(i) + ✏k p! F kC(i),  bF kC(i) +
✏k
p!  F kC(i), bF kT (j) + ✏k p! F kT (j), and   bF kT (j) + ✏k p!  F kT (j) for all i, j = 1, .., L  1. By
Theorem 11.9 in Severini (2005), limn!1 P0
 kbn   b⇤k2 > ⌘C   = 0. Thus,
lim
n!1
P0(| R,Xl,k    R,Xl,k | > ⌘)  limn!1P0
⇣
kbn   b⇤k2 > ⌘
C
⌘
= 0,
so limn!1 P0(| R,Xl,k    R,Xl,k | > ⌘) = 0. The choice of ⌘ was arbitrary, so we conclude that
 
R,X
l,k
p!  R,Xl,k . Analogously, it can be shown that  
R,X
u,k
p!  R,Xu,k . Thus, (II) holds. We
conclude that  
R,X
l and  
R,X
u are consistent estimators of  
R,X
l and  
R,X
u , respectively.
Lemma 1. Consider the linear programming problem:
min
x
cTx, subject to Ax  b, x   0, (16)
where A 2 Rd1⇥d2. Let f(b) denote the optimal value of the linear program as a function of
b, where we use the convention that f(b) = 1 if the problem is infeasible. Consider any b⇤
such that f(b⇤) is finite (i.e., the linear program is bounded and feasible at b = b⇤). Then
there exists a constant C > 0 such that for any b0 satisfying f(b0) <1, we have
|f(b0)  f(b⇤)|  Ckb0   b⇤k2.
Proof. We assume the reader has familiarity with linear programming terminology. (For an
overview of linear programming relevant to our proof, please see Chapter 6 of Dantzig and
Thapa (2006).) Without loss of generality we can drop the x   0 term in the linear program
(16) since these constraints can be incorporated into the set of inequalities Ax  b. Consider
the dual linear program:
max
y
bTy, subject to ATy = c, y   0.
It is bounded and feasible at b = b⇤ and at b = b0, which follows from the conditions in the
lemma. Let V ⇤ denote the set of vertices of the dual linear program, which is non-empty,
finite, and only depends on A and c (and does not depend on b). Since the optimal value of
7
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the dual problem occurs at a vertex, it equals max{yT b : y 2 V ⇤}, for any vector b for which
the linear program is bounded and feasible (which includes the cases b = b⇤ and b = b0).
By strong duality, for each b 2 {b0, b⇤}, the optimal value of the primal (original) linear
program equals the optimal value of the dual linear program, and therefore
|f(b0)  f(b⇤)| =   max
y2V ⇤
yT b0  max
y2V ⇤
yT b⇤
    max
y2V ⇤
|yT (b0   b⇤)|  max
y2V ⇤
kyk2kb0   b⇤k2,
where the last inequality follows from the Cauchy-Schwartz inequality. The lemma is proved
for C = maxy2V ⇤ kyk2, which is finite since V ⇤ is non-empty and has a finite number of
elements.
Lemma 2. Let P0 be the true joint distribution on (X, YC , YT ). Suppose P0 is consistent
with R and Assumptions 1 and 2 hold. Then ✏k p! 0 for any k, as n!1.
Proof. In this proof, we will show that limn!1 P0(|✏k   0| > ⌘) = 0 for any ⌘ > 0.
Choose any k = 1, .., K. Fix n 2 N. Consider the following linear program, referred to
as LP:
min
x
cTx, subject to Ax  b, x   0.
Define x and c as:
x =
⇥
[⇡ki,1]
L
i=1, [⇡
k
i,2]
L
i=1, . . . , [⇡
k
i,L]
L
i=1, ✏k
⇤T
,
cT =
⇥
01⇥L2 , 1
⇤
,
where 01⇥L2 is a row vector of length L2 containing only zeroes. Define A as the matrix that
satisfies:
Ax =
P
g(i,j)=0 ⇡
k
i,j,
PL
i=1
PL
j=1 ⇡
k
i,j,  
PL
i=1
PL
j=1 ⇡
k
i,j, [
Pi
i0=1
PL
j=1 ⇡
k
i0,j   ✏k]L 1i=1 ,
[ Pii0=1PLj=1 ⇡ki0,j   ✏k]L 1i=1 , [Pjj0=1PLi=1 ⇡ki,j0   ✏k]L 1j=1 , [ Pjj0=1PLi=1 ⇡ki,j0   ✏k]L 1j=1  T .
Let f(b) be the optimal value of LP as a function of b. Define:
b⇤ =
h
0, 1,  1, ⇥F kC(i)⇤L 1i=1 , ⇥ F kC(i)⇤L 1i=1 , ⇥F kT (j)⇤L 1j=1 , ⇥ F kT (j)⇤L 1j=1 iT ,
bn =

0, 1,  1,
h bF kC(i)iL 1
i=1
,
h
  bF kC(i)iL 1
i=1
,
h bF kT (j)iL 1
j=1
,
h
  bF kT (j)iL 1
j=1
 T
.
By Assumption 1, f(b⇤) = 0. When b = bn, LP is equivalent to the linear program for ✏k,
so f(bn) = ✏k  1. By Lemma 1, there exists a constant C > 0 such that |f(b)   f(b⇤)| 
Ckb  b⇤k2 for any b such that f(b) <1. This means that |f(bn)  f(b⇤)|  Ckbn   b⇤k2.
Choose any ⌘ > 0. Then
P0(|✏k   0| > ⌘) = P0(|f(bn)  f(b⇤)| > ⌘)  P0
⇣
kbn   b⇤k2 > ⌘
C
⌘
.
It follows from the Weak Law of Large Numbers that bn converges to b⇤ in probability, and
so the right side of the above display converges to 0 as n!1, completing the proof of the
lemma.
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Table 1: Estimated Bounds on the Fraction who Benefit, with respect to 30-day mRS Score.
The bound estimates in (a) are for the entire population, and those in (b) are for each
subpopulation.
(a) For the population
Without BV With BV
l u ✏ l u
No assumptions 0.07 0.61 0 0.17 0.52
Benefit at most 5 0.07 0.61 0 0.17 0.52
at most 4 0.07 0.61 0 0.17 0.52
at most 3 0.07 0.61 0 0.17 0.52
at most 2 0.09 0.61 0 0.17 0.52
at most 1 0.12 0.61 0 0.22 0.52
Harm at most 5 0.07 0.61 0 0.17 0.52
at most 4 0.07 0.61 0 0.17 0.52
at most 3 0.07 0.61 0 0.17 0.52
at most 2 0.07 0.59 0 0.17 0.52
at most 1 0.07 0.50 0 0.17 0.45
No Harm 0.03 0.26 0.02 0.15 0.34
(b) For each subpopulation
Non-severe Severe
l u ✏ l u ✏
No assumptions 0.04 0.41 0 0.26 0.60 0
Benefit at most 5 0.04 0.41 0 0.26 0.60 0
at most 4 0.04 0.41 0 0.26 0.60 0
at most 3 0.04 0.41 0 0.26 0.60 0
at most 2 0.04 0.41 0 0.26 0.60 0
at most 1 0.06 0.41 0 0.33 0.60 0
Harm at most 5 0.04 0.41 0 0.26 0.60 0
at most 4 0.04 0.41 0 0.26 0.60 0
at most 3 0.04 0.41 0 0.26 0.60 0
at most 2 0.04 0.41 0 0.26 0.60 0
at most 1 0.04 0.26 0 0.26 0.60 0
No Harm 0.00 0.37 0.10 0.26 0.33 0
BV=baseline variable, l=lower bound estimate, u=upper bound estimate,
✏=relaxation term.
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Table 2: Estimated Bounds on the Fraction who Benefit, with respect to 180-day mRS
Score. The bound estimates in (a) are for the entire population, and those in (b) are for each
subpopulation.
(a) For the population
Without BV With BV
l u ✏ l u
No assumptions 0.10 0.73 0 0.13 0.64
Benefit at most 5 0.10 0.73 0 0.13 0.64
at most 4 0.10 0.73 0 0.13 0.64
at most 3 0.10 0.73 0 0.14 0.64
at most 2 0.12 0.73 0 0.18 0.64
at most 1 0.18 0.64 0 0.20 0.65
Harm at most 5 0.10 0.73 0 0.13 0.64
at most 4 0.10 0.73 0 0.13 0.64
at most 3 0.10 0.64 0 0.13 0.63
at most 2 0.10 0.62 0 0.13 0.63
at most 1 0.10 0.42 0 0.12 0.50
No Harm 0.10 0.18 0 0.12 0.50
(b) For each subpopulation
Non-severe Severe
l u ✏ l u ✏
No assumptions 0.01 0.59 0 0.22 0.68 0
Benefit at most 5 0.01 0.59 0 0.22 0.68 0
at most 4 0.01 0.59 0 0.22 0.68 0
at most 3 0.01 0.59 0 0.25 0.68 0
at most 2 0.01 0.59 0 0.32 0.68 0
at most 1 0.01 0.57 0 0.34 0.71 0.03
Harm at most 5 0.01 0.59 0 0.22 0.68 0
at most 4 0.01 0.59 0 0.22 0.68 0
at most 3 0.01 0.57 0 0.22 0.68 0
at most 2 0.01 0.57 0 0.22 0.68 0
at most 1 0.00 0.31 0.04 0.22 0.64 0
No Harm 0.00 0.44 0.08 0.22 0.55 0
BV=baseline variable, l=lower bound estimate, u=upper bound estimate,
✏=relaxation term.
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Table 3: Estimated Bounds on the Fraction who Benefit, with respect to Reduction in Clot
Volume (ordinal). The bound estimates in (a) are for the entire population, and those in (b)
are for each individual subpopulation.
(a) For the population
Without BV With BV
l u ✏ l u
No assumptions 0.82 0.99 0 0.83 0.98
Benefit at most 4 0.82 0.99 0 0.86 0.98
at most 3 0.96 0.99 0.001 0.88 0.98
at most 2 0.70 1.00 0.23 0.70 1.00
at most 1 0.52 1.00 0.35 0.37 1.00
Harm at most 4 0.82 0.99 0 0.83 0.98
at most 3 0.82 0.99 0 0.83 0.98
at most 2 0.82 0.99 0 0.83 0.98
at most 1 0.82 0.99 0 0.83 0.98
No Harm 0.82 0.99 0 0.83 0.98
(b) For each subpopulation
Low Clot Volume High Clot Volume
l u ✏ l u ✏
No assumptions 0.81 0.96 0 0.86 1.00 0
Benefit at most 4 0.81 0.96 0 0.91 1.00 0
at most 3 0.85 0.96 0 0.91 1.00 0.05
at most 2 0.71 1.00 0.22 0.70 1.00 0.23
at most 1 0.19 1.00 0.62 0.55 1.00 0.38
Harm at most 4 0.81 0.96 0 0.86 1.00 0
at most 3 0.81 0.96 0 0.86 1.00 0
at most 2 0.81 0.96 0 0.86 1.00 0
at most 1 0.81 0.96 0 0.86 1.00 0
No Harm 0.81 0.96 0 0.86 1.00 0
BV=baseline variable, l=lower bound estimate, u=upper bound estimate,
✏=relaxation term.
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